STOCK TITAN

Imunon (IMNN) director granted 5,557 shares in lieu of board fees

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Imunon, Inc. director Christine A. Pellizzari received a grant of company common stock as part of her board compensation. She was awarded 5,557 shares of common stock, valued at $2.20 per share, in lieu of a portion of her cash board fees. Following this grant, she directly holds 8,142 shares of Imunon common stock. This is a compensation-related, not open-market, acquisition of shares.

Positive

  • None.

Negative

  • None.
Insider Pellizzari Christine A
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 5,557 $2.20 $12K
Holdings After Transaction: Common Stock — 8,142 shares (Direct)
Footnotes (1)
  1. F1. Stock granted in lieu of cash for portion of board fees
Shares granted 5,557 shares Common Stock award on May 22, 2026
Grant valuation price $2.20 per share Reported value for stock grant
Shares held after grant 8,142 shares Direct holdings following the transaction
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
in lieu of cash financial
"Stock granted in lieu of cash for portion of board fees"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Imunon (IMNN) report for Christine Pellizzari?

Imunon reported that director Christine A. Pellizzari received a grant of 5,557 shares of common stock. The shares were awarded as part of her board compensation rather than bought on the open market.

At what price were the Imunon (IMNN) shares granted to Christine Pellizzari valued?

The 5,557 Imunon common shares granted to Christine Pellizzari were valued at $2.20 per share. This price is used for reporting the compensation value of the stock award in the insider filing.

How many Imunon (IMNN) shares does Christine Pellizzari hold after the grant?

After the stock grant, Christine Pellizzari directly holds 8,142 shares of Imunon common stock. This total reflects her position following the 5,557-share award reported in the insider transaction.

Was the Imunon (IMNN) stock grant to Christine Pellizzari a market purchase?

No, the transaction was not a market purchase. The filing notes the stock was granted in lieu of cash for a portion of her board fees, making it compensation rather than an open-market buy.

What does the Form 4 stock grant mean for Imunon (IMNN) director compensation?

The Form 4 shows part of director Christine Pellizzari’s board fees paid in stock instead of cash. This structure aligns director compensation more closely with shareholder interests by increasing her equity stake in the company.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pellizzari Christine A

(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100

(Street)
LAWRENCEVILLE NEW JERSEY 08648

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026A5,557(1)A$2.28,142D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for portion of board fees
Remarks:
On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.
/s/ Susan Eylward, Attorney-in-Fact for Christine Pellizzari05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)